

On September 30, 2016, the Board of Directors of Karyopharm Therapeutics Inc. (the “Company”) approved an amendment to the Company’s Code of Business Conduct and Ethics (the “Code of Conduct”) to include therein the notice of immunity required by the Defend Trade Secrets Act of 2016.

On February 9, 2017, the Board of Directors of the Company approved an amendment to the Code of Conduct to (i) include a clarifying statement that the Code of Conduct does not prohibit anyone subject to the Code of Conduct from engaging in concerted activity protected by the rules and regulations of the National Labor Relations Board and (ii) revise the confidentiality section to include a definition and provide illustrative examples of proprietary information the confidentiality of which is required to be maintained.